Your browser is no longer supported. Please, upgrade your browser.
Settings
BCYC Bicycle Therapeutics plc daily Stock Chart
BCYC [NASD]
Bicycle Therapeutics plc
Index- P/E- EPS (ttm)-2.07 Insider Own0.90% Shs Outstand18.08M Perf Week-4.08%
Market Cap381.91M Forward P/E- EPS next Y-2.54 Insider Trans-2.56% Shs Float4.33M Perf Month5.32%
Income-37.30M PEG- EPS next Q-0.50 Inst Own32.90% Short Float3.56% Perf Quarter12.22%
Sales8.60M P/S44.41 EPS this Y-124.50% Inst Trans5.86% Short Ratio2.06 Perf Half Y48.86%
Book/sh3.93 P/B4.84 EPS next Y-14.40% ROA-31.50% Target Price23.86 Perf Year63.04%
Cash/sh4.82 P/C3.94 EPS next 5Y- ROE-43.70% 52W Range7.50 - 21.59 Perf YTD101.59%
Dividend- P/FCF- EPS past 5Y- ROI-27.90% 52W High-11.95% Beta-
Dividend %- Quick Ratio6.60 Sales past 5Y- Gross Margin- 52W Low153.47% ATR1.56
Employees72 Current Ratio6.60 Sales Q/Q6.70% Oper. Margin- RSI (14)52.76 Volatility8.88% 8.35%
OptionableNo Debt/Eq0.00 EPS Q/Q-17.40% Profit Margin- Rel Volume0.32 Prev Close18.39
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume75.07K Price19.01
Recom1.60 SMA203.00% SMA507.36% SMA20029.35% Volume24,320 Change3.37%
Jun-12-20Initiated Oppenheimer Outperform
Apr-17-20Initiated H.C. Wainwright Buy $25
Nov-14-19Initiated ROTH Capital Buy $17
Sep-11-19Upgrade Goldman Neutral → Buy $14
Jun-17-19Initiated Piper Jaffray Overweight $20
Jun-17-19Initiated Jefferies Buy $22
Jun-17-19Initiated Goldman Neutral $14
Jun-17-19Initiated Canaccord Genuity Buy $22
Sep-19-20 08:03AM  
Sep-18-20 07:30AM  
Sep-14-20 06:59AM  
Sep-10-20 04:05PM  
Sep-03-20 06:59AM  
Sep-02-20 06:59AM  
Sep-01-20 06:59AM  
Aug-06-20 08:03AM  
Aug-05-20 04:05PM  
06:59AM  
Jun-24-20 08:37AM  
Jun-23-20 06:59AM  
Jun-22-20 06:59AM  
Jun-13-20 07:56AM  
Jun-12-20 06:46PM  
May-27-20 06:59AM  
May-15-20 06:59AM  
May-13-20 05:09PM  
May-12-20 06:59AM  
May-08-20 09:32AM  
May-07-20 06:59AM  
May-06-20 06:59AM  
May-05-20 06:59AM  
Apr-23-20 06:59AM  
Apr-08-20 07:16AM  
Apr-07-20 06:59AM  
Apr-06-20 06:59AM  
Mar-31-20 07:22AM  
Mar-30-20 11:30AM  
Mar-17-20 06:45AM  
Mar-16-20 08:38AM  
Mar-13-20 12:00PM  
11:30AM  
10:18AM  
Mar-10-20 06:59AM  
Feb-25-20 06:59AM  
Jan-07-20 07:00AM  
Dec-22-19 06:09PM  
Nov-26-19 07:00AM  
07:00AM  
Nov-14-19 07:00AM  
Nov-13-19 07:00AM  
Nov-07-19 07:00AM  
Nov-05-19 08:14AM  
Oct-31-19 07:00AM  
Oct-29-19 07:00AM  
Oct-22-19 03:00AM  
Oct-16-19 04:33PM  
Sep-28-19 06:00AM  
Sep-24-19 07:00AM  
Sep-19-19 09:23AM  
Aug-08-19 07:00AM  
Jul-24-19 08:00AM  
Jul-01-19 07:46AM  
07:30AM  
May-23-19 01:09PM  
09:15AM  
08:55AM  
May-22-19 09:49PM  
May-21-19 04:45PM  
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/IIa clinical trial targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase I clinical trials for the treatment of diabetic macular edema. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. Bicycle Therapeutics plc has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. The company was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GLAXOSMITHKLINE PLC10% OwnerJul 15Sale19.403,14761,0451,910,531Sep 18 12:04 PM
GLAXOSMITHKLINE PLC10% OwnerJul 14Sale19.271,59730,7811,913,678Sep 18 12:04 PM